317 related articles for article (PubMed ID: 25911747)
1. B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.
Wu MR; Zhang T; Gacerez AT; Coupet TA; DeMars LR; Sentman CL
J Immunol; 2015 Jun; 194(11):5305-11. PubMed ID: 25911747
[TBL] [Abstract][Full Text] [Related]
2. B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity.
Wu MR; Zhang T; DeMars LR; Sentman CL
Gene Ther; 2015 Aug; 22(8):675-84. PubMed ID: 25830550
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression.
Gacerez AT; Hua CK; Ackerman ME; Sentman CL
Cancer Immunol Immunother; 2018 May; 67(5):749-759. PubMed ID: 29453518
[TBL] [Abstract][Full Text] [Related]
4. B7H6-derived peptides trigger TNF-α-dependent immunostimulatory activity of lymphocytic NK92-MI cells.
Phillips M; Romeo F; Bitsaktsis C; Sabatino D
Biopolymers; 2016 Sep; 106(5):658-72. PubMed ID: 27216712
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
Zhang T; Sentman CL
Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
[TBL] [Abstract][Full Text] [Related]
6. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.
Zhang T; Wu MR; Sentman CL
J Immunol; 2012 Sep; 189(5):2290-9. PubMed ID: 22851709
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
[No Abstract] [Full Text] [Related]
8. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
9. The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance.
Kilian M; Friedrich MJ; Lu KH; Vonhören D; Jansky S; Michel J; Keib A; Stange S; Hackert N; Kehl N; Hahn M; Habel A; Jung S; Jähne K; Sahm F; Betge J; Cerwenka A; Westermann F; Dreger P; Raab MS; Meindl-Beinker NM; Ebert M; Bunse L; Müller-Tidow C; Schmitt M; Platten M
Sci Immunol; 2024 May; 9(95):eadj7970. PubMed ID: 38701193
[TBL] [Abstract][Full Text] [Related]
10. T-bet promotes potent antitumor activity of CD4
Gacerez AT; Sentman CL
Cancer Gene Ther; 2018 Jun; 25(5-6):117-128. PubMed ID: 29515240
[TBL] [Abstract][Full Text] [Related]
11. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
[TBL] [Abstract][Full Text] [Related]
12. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
[TBL] [Abstract][Full Text] [Related]
13. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
[TBL] [Abstract][Full Text] [Related]
14. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
[No Abstract] [Full Text] [Related]
15. Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.
Hua CK; Gacerez AT; Sentman CL; Ackerman ME
Protein Eng Des Sel; 2017 Oct; 30(10):713-721. PubMed ID: 29040754
[TBL] [Abstract][Full Text] [Related]
16. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
17. B7H6 is a functional ligand for NKp30 in rat and cattle and determines NKp30 reactivity toward human cancer cell lines.
Bjørnsen EG; Thiruchelvam-Kyle L; Hoelsbrekken SE; Henden C; Saether PC; Boysen P; Daws MR; Dissen E
Eur J Immunol; 2019 Jan; 49(1):54-65. PubMed ID: 30512185
[TBL] [Abstract][Full Text] [Related]
18. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
Spear P; Barber A; Rynda-Apple A; Sentman CL
Immunol Cell Biol; 2013 Jul; 91(6):435-40. PubMed ID: 23628805
[TBL] [Abstract][Full Text] [Related]
19. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
[TBL] [Abstract][Full Text] [Related]
20. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]